Clinical trials: Empagliflozin
ST-elevation Myocardial Infarction (STEMI), Acute Myocardial Infarction (AMI)
Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patients
The goal of this clinical trial is to learn if giving the drug empagliflozin before versus after a heart procedure called primary PCI (percutaneous coronary intervention) affects how much heart muscle is damaged during a heart…
- Conditions
- ST-elevation Myocardial Infarction (STEMI), Acute Myocardial Infarction (AMI), Coronary Artery Disease
- Trial name
- TEMPO-STEMI (NCT07749014)
- Testing
- empagliflozin
- Where
- Pakistan
- Volunteers
- 480 people
- Sponsor
- Rehman Medical Institute - RMI
Gout and Hyperuricemia
SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial
SAVE-Care (Sodium Glucose Cotransporter-2 inhibitors [SGLT2i] As Novel Gout Care) Trial is a double-blind randomized placebo-controlled trial (RCT) designed to assess the effect of empagliflozin on serum urate [SU] levels of gout…
- Trial name
- SAVE-Care (NCT06674109)
- Testing
- Empagliflozin 10 mg
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Type 2 Diabetes, High Blood Pressure
Polypill for Prevention of Cardiomyopathy
This study will investigate the utility of a polypill-based strategy for patients with type 2 diabetes mellitus and high risk of heart failure (HF), as assessed via the WATCH-DM risk score.
- Trial name
- PolyPreventHF (NCT06143566)
- Testing
- Polypill, Combined prescription of the individual medications
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Texas Southwestern Medical Center
Pancreatitis, Chronic, Pancreatitis, Acute
Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis Associated Diabetes Mellitus
The purpose of this study is to evaluate efficacy of pioglitazone (PIO) versus empagliflozin (EMPA) to improve glycemic control in people with Chronic Pancreatitis (CP) or Recurrent Acute Pancreatitis (RAP) or Acute Pancreatitis…
- Conditions
- Pancreatitis, Chronic, Pancreatitis, Acute, Diabetes Mellitus
- Trial name
- PEP-DM (NCT06729996)
- Testing
- Pioglitazone (PIO), Empagliflozin (EMPA)
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Moderate Aortic Valve Stenosis
The Role of SGLT2i in Management of Moderate AS
Background: The aortic valve is like a door in the heart that lets blood flow out to the body. Over time, this valve can get worn out and become too narrow, leading to a condition called aortic stenosis.
- Trial name
- NCT06469645
- Testing
- Empagliflozin 10 MG
- Where
- United Kingdom
- Volunteers
- 104 people
- Sponsor
- University of East Anglia
Diabetes Mellitus, Type 2
Comparative Effectiveness of Empagliflozin in the US
Empagliflozin, a sodium glucose co-transporter 2 (SGLT-2) inhibitor, was launched as a treatment for type 2 diabetes mellitus (T2DM) in the U.S. in August 2014.
- Trial name
- NCT03363464
- Testing
- Empagliflozin, DPP-4 inhibitor, GLP-1 receptor agonist
- Where
- United States
- Volunteers
- 230,000 people
- Sponsor
- Boehringer Ingelheim
Partial Islet Function, TPIAT
SGLT2i Therapy in Islet Transplantation (SIT)
This pilot clinical trial is designed to gather preliminary data on the efficacy and safety of empagliflozin, a diabetes drug in the sodium-glucose cotransporter 2 inhibitor (SGLT2i) class, in islet autotransplant recipients who…
- Conditions
- Partial Islet Function, TPIAT, Diabetes
- Trial name
- NCT07228195
- Testing
- Empagliflozin 25 MG Oral Tablet, Empagliflozin 10 MG Oral Tablet [Jardiance]
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Minnesota
Type 2 Diabetes
SGLTi, Hepatic Glucose Production and Ketogenesis
In this study, we will test the hypothesis that distinct mechanisms account for the SGLT2i-induced stimulation of ketogenesis and lipolysis versus endogenous (hepatic) glucose production in patients with type 2 diabetes (T2D) and…
- Trial name
- NCT05960656
- Testing
- Empagliflozin 25 MG
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes
SGLT2i, Hepatic Glucose Production, and SNS
In this study, PI will test the hypothesis that distinct mechanisms account for the SGLT2i-induced stimulation of ketogenesis and lipolysis versus endogenous (hepatic) glucose production in patients with type 2 diabetes (T2D)…
- Trial name
- NCT07053293
- Testing
- Empagliflozin 25 MG
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes
SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia
To examine the 2-HIT hypothesis that the SGLT2i-induced stimulation of EGP, lipolysis, and ketone production requires the combination of volume depletion plus insulinopenia in T2D individuals.
- Trial name
- NCT07053306
- Testing
- Empagliflozin 25 MG
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes
SGLT2i, Pioglitazone, and Ketone Production in T2D
To examine whether the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D individuals can be blocked by pioglitazone (which has direct hepatic and adipose tissue effects).
- Trial name
- NCT07053319
- Testing
- Empagliflozin 25 MG, Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Lupus Nephritis (LN)
The Efficacy of Empagliflozin on Kidney Functions in Lupus Nephritis Population
Systemic lupus erythematosis (SLE) is a chronic, most probably auto-immune multisystem disease marked by relapsing-remitting course and the formation of a range of autoantibodies.
- Trial name
- NCT07700940
- Testing
- Empagliflozin (25 Mg Tab) along with standard medical therapy
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Ahmed Yehia Ismail
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known to trigger injury and inflammation in the kidney and is therefore thought to…
- Trial name
- CONFIDENCE (NCT05254002)
- Testing
- Finerenone (BAY94-8862 ) 10 mg, Empagliflozin, Finerenone (BAY94-8862 ) 20 mg
- Where
- 173 sites in United States, Belgium and 12 more
- Volunteers
- 1,664 people
- Sponsor
- Bayer
Heart Failure With Reduced Ejection Fraction, Chronic Heart Failure
Emulation of the EMPEROR-Reduced Trial Using Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Trial name
- NCT07599345
- Testing
- Empagliflozin, Sitagliptin
- Where
- United States
- Volunteers
- 23,955 people
- Sponsor
- Brigham and Women's Hospital
Type 2 Diabetes Mellitus (T2DM), Cognitive Dysfunction
SGLT2 Inhibitors and Cognitive Function in Adults With Type 2 Diabetes (SaveMinD)
This study is a prospective, randomized, open-label trial with blinded outcome assessment (PROBE design) designed to evaluate the effects of sodium-glucose cotransporter-2 (SGLT2) inhibitor therapy on cognitive function in adults…
- Trial name
- SaveMinD (NCT07694596)
- Testing
- SGLT2 Inhibitor, Standard Diabetes Care
- Where
- Slovenia
- Volunteers
- 200 people
- Sponsor
- University of Primorska
Heart Failure With Preserved Ejection Fraction, Chronic Heart Failure
Emulation of the EMPEROR-Preserved Trial Using Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Conditions
- Heart Failure With Preserved Ejection Fraction, Chronic Heart Failure, Type 2 Diabetes Mellitus
- Trial name
- NCT07599293
- Testing
- Empagliflozin, Sitagliptin
- Where
- United States
- Volunteers
- 39,614 people
- Sponsor
- Brigham and Women's Hospital
Heart Failure
the Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients
the study to investigate the efficacy of empagiflozin in pediatric heart failure
- Trial name
- NCT07692256
- Testing
- Empagliflozin (EMPA), Standard medical treatment
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Type 2 Diabetes Mellitus (T2DM)
Bioequivalence Study to Compare Empagliflozin/ Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg
An open label, randomized, two-period, two treatment, two-sequence, crossover, balanced, single dose oral bioequivalence study to compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet versus Synjardy XR tablets…
- Trial name
- NCT07694115
- Testing
- Empagliflozin / Metformin Extended-Release Tablet, Synjardy XR tablets
- Where
- India
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH)
Combined Active Treatment in Type 2 Diabetes With NASH
The aim of this multicentre, prospective, placebo-controlled, double-blind, randomized, 3-arm parallel group, interventional study is to assess for the first time the effects of either a combined therapy with the…
- Conditions
- Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD)
- Trial name
- COMBAT_T2_NASH (NCT04639414)
- Testing
- Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector
- Where
- 26 sites in Austria, Germany
- Volunteers
- 192 people
- Sponsor
- German Diabetes Center
Type 2 Diabetes Mellitus (T2DM), Cardiovascular Diseases
Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release Tablets
An open label, randomized, two-period, two treatment, two-sequence, crossover, balanced, single dose oral bioequivalence study to compare Empagliflozin/ Linagliptin/ Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet versus…
- Trial name
- NCT07691203
- Testing
- Empagliflozin/Linagliptin/Metformin HCl Extended Release Tablet, Trijardy® XR Tablets
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi